July 1, 2017 - To functionally determine the role of IRAK4 in MDS/AML pathogenesis, we utilized CA-4948, a potent, oral, small-molecule inhibitor of IRAK4, to assess the effect of inhibiting IRAK4 catalytic activity. In vitro, CA-4948 blocked downstream NF-κB pathway signaling, including secretion of ...

Small molecule potent IRAK4 inhibitors from a novel bicyclic heterocycle class were designed and synthesized based on hits identified from Aurigene’s compound library. The advanced lead compound, CA-4948, demonstrated good cellular activity in ...

CA-4948: An IRAK-4 inhibitor. CAS Number: 1801343-74-7. Purity: ≥98%.

Emavusertib (CA-4948) is a selective, potent and orally active IRAK4/FLT3 inhibitor. Emavusertib has an IC50 of 57 nM for IRAK4 in a FRET kinase assay. Emavusertib shows anti-tumor activity. - Mechanism of Action & Protocol.

February 20, 2020 - Study record managers: refer to the Data Element Definitions if submitting registration or results information

An ongoing challenge in cancer is the management of primary and metastatic brain malignancies. This is partly due to restrictions of the blood-brain barrier and their unique microenvironment. These challenges are most evident in cancers such as lymphoma ...

The IUPHAR/BPS Guide to Pharmacology. emavusertib ligand page.

May 12, 2021 - /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today...

Cancer Research publishes impactful original studies, reviews, and opinion pieces of high significance to the broad cancer research community. Cancer Research seeks manuscripts that offer conceptual or technological advances leading to basic and translational insights into cancer biology.

Introduction and PurposeIRAK4 kinase activity is essential for signaling downstream of toll-like receptors (TLR) and the interleukin-1 receptor (IL-1R…

November 29, 2018 - Abstract. Background: IRAK4 kinase activity is required for toll-like receptor (TLR) and interleukin-1 receptor (IL-1R) signaling in a variety of myeloid a

ASCO’s publications—including the Society’s flagship publication, the Journal of Clinical Oncology—serve readers as the most credible, authoritative, peer-reviewed resources for significant clinical oncology research that informs the delivery of high-quality patient care across the globe.

August 21, 2024 - Emavusertib (CA 4948) is an orally administered small molecule, and a reversible inhibitor of interleukin-1 receptor-associated kinase 4 (IRAK4) and fms-like

March 11, 2024 - The updated results of an ongoing phase 1/2 study indicated that CA-4948 achieved promising responses and a tolerable safety profile in patients with relapsed/refractory acute myeloid leukemia and myelodysplastic syndromes.

June 11, 2021 - Dentzer added, "We are especially pleased with the outcomes seen to date for patients with spliceosome or FLT3 mutations. All three patients with a spliceosome mutation achieved an objective response. The FLT3 patient also achieved an objective response and, after two cycles of CA-4948, the ...

Patients and caregivers are often interested in learning more about clinical trials for brain tumors. It can be confusing and overwhelming to understand what clinical trial may be best for you or your loved one.

June 25, 2024 - Shares of oncology focussed US biotech firm Curis (Nasdaq: CRIS) closed up 65.5% at $16.27 yesterday, after it announced that two abstracts for CA-4948, a novel, small molecule IRAK4 inhibitor, have been accepted for oral and poster presentation at the European Hematology Association 2021 Virtual ...

December 10, 2023 - The search filters will allow you to restrict your search by date, session type, or abstract category and are all optional. Hold down the Ctrl key while selecting to choose more than one option in each list, or hold down the Shift key to select a range · -Author name in bold denotes the presenting ...